



Targeting Transcription Factors and Oncogenic Proteins for Cancer Therapy

Guest Editor:

Dr. Gautam Sethi

Department of Pharmacology,
Yong Loo Lin School of Medicine,
National University of Singapore,
Singapore 117597, Singapore

Deadline for manuscript
submissions:

closed (30 November 2020)

Message from the Guest Editor

Dear Colleagues,

The activation of oncogenic transcription factors (NF- κ B, STAT3, STAT5, AP-1, etc.) and proteins (Ras, Raf, Src, etc.) plays an important role in tumorigenesis. The mechanisms(s) regulating the activation of these transcription factors and proteins are complex and constantly evolving. The current issue will explore in detail the role of oncogenic transcription factors/proteins in carcinogenesis and highlight novel pharmacological strategies that can be evolved to target them and subsequently mitigate the processes of abnormal proliferation and survival of tumor cells.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)